Crown Laboratories Finalizes Acquisition of Revance Therapeutics
Crown Laboratories, Inc., a global leader in innovative skincare solutions and a part of the Hildred Capital portfolio, has officially closed its acquisition of Revance Therapeutics, Inc., a biotechnology company focused on advancing healthcare with innovative aesthetic and therapeutic products. This acquisition marks a significant milestone in Crown’s growth, bringing together two dynamic players in the skincare and aesthetics industry.
Jeff Bedard, the Founder and CEO of Crown Laboratories, expressed excitement about the successful acquisition, emphasizing its strategic importance for the company’s future. “We are excited to officially welcome Revance to the Crown family. This acquisition strengthens our leadership position and enhances our ability to deliver innovative solutions to customers,” he said.
He further highlighted how the acquisition positions Crown to provide a comprehensive portfolio representing the three pillars of facial aesthetics – relax, restore, and regenerate. With these offerings, Crown aims to further solidify its position as a global leader in the aesthetics and skincare industry. Bedard also pointed out that Crown’s highly trained and experienced sales force will play a key role in supporting these new products, enabling Crown to create long-term value for its stakeholders.
Andrew Goldman and David Solomon, Co-Founders and Managing Partners of Hildred Capital, also shared their enthusiasm regarding the deal’s completion. “We are thrilled to celebrate the successful completion of this transaction and to commence the integration of two innovative companies,” they stated. The Hildred team sees the merger as an opportunity to create a dominant player in the rapidly evolving skincare and aesthetics markets.
Hildred remains committed to supporting healthcare providers and aesthetic practices with science-backed products that deliver real results. They expressed particular excitement about the combined potential of Revance’s and Crown’s offerings, especially in relation to Revance’s ongoing collaboration with Teoxane to expand the RHA® Collection by Teoxane in the U.S. market.
The acquisition of Revance complements Crown’s existing portfolio of premium skincare and therapeutic products. Crown, a privately held company, has established itself as a leader in dermatology and aesthetics, delivering a diverse range of skincare solutions designed to improve the quality of life for its consumers. The company’s innovation, along with its focus on skin science, has led to a growing presence in more than 50 countries worldwide. Crown has also earned a place on the Inc. 5000 Fastest Growing Privately Held Companies List for eleven years running, underscoring its remarkable growth and success.
Revance, which is based in Nashville, Tennessee, is known for its innovative aesthetic and therapeutic treatments that aim to improve patient outcomes and enhance physician experiences. One of its flagship products, DAXXIFY (DaxibotulinumtoxinA-lanm), is a botulinum toxin injection that represents a significant advancement in aesthetics, offering patients longer-lasting results compared to traditional botulinum toxin products.
Additionally, Revance is the exclusive U.S. distributor for the RHA Collection of dermal fillers, which are manufactured by Teoxane SA in Switzerland. The RHA Collection features Resilient Hyaluronic Acid® technology and has gained recognition for its high-quality formulations and ability to provide natural-looking results.
As part of its strategic growth, Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, and with Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China. These global partnerships reflect Revance’s commitment to expanding its reach and establishing a broader footprint in the international market.
With the closing of the acquisition, Crown is well-positioned to leverage Revance’s advanced portfolio of products, strengthening its standing in the competitive aesthetics and skincare industry. The two companies’ complementary offerings will allow Crown to provide a more robust range of solutions to healthcare providers and patients alike, helping to meet the growing demand for advanced skincare and aesthetic treatments.
The company offers an array of high-quality skincare solutions, including the well-known PanOxyl and Blue Lizard brands, as well as SkinPen and StriVectin, which are registered trademarks of Bellus Medical, LLC and StriVectin Operating Company, Inc., respectively.
Revance Therapeutics, with its proprietary technologies and market-leading products, continues to set the standard for aesthetic and therapeutic care. The company’s diverse product offerings, including DAXXIFY and the RHA Collection, place it at the forefront of the skincare industry, addressing both aesthetic and medical needs. More information about Revance can be found on its websites: Revance.com, RevanceAesthetics.com, and DAXXIFY.com.
Hildred Capital, the private equity firm that facilitated the acquisition, brings its wealth of experience in healthcare investments to the deal. The firm specializes in operationally intensive, control-oriented investments in lower middle-market companies. With more than $2.65 billion in assets under management, Hildred Capital continues to support innovative companies in the healthcare sector, helping them achieve strategic growth and long-term success.
The successful closing of this acquisition marks the beginning of an exciting new chapter for both Crown Laboratories and Revance Therapeutics, as they work together to deliver cutting-edge products and solutions to customers in the dynamic skincare and aesthetics market.
